{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1361418520820982016.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1111/j.1365-2230.2004.01618.x"}},{"identifier":{"@type":"URI","@value":"https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1365-2230.2004.01618.x"}},{"identifier":{"@type":"URI","@value":"http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2230.2004.01618.x/fullpdf"}},{"identifier":{"@type":"PMID","@value":"15347340"}}],"dc:title":[{"@value":"Effects of bepotastine, cetirizine, fexofenadine, and olopatadine on histamine-induced wheal-and flare-response, sedation, and psychomotor performance"}],"description":[{"notation":[{"@value":"Although many antihistamines are now in clinical use, few studies directly compare their pharmacodynamic and sedative activities in humans in vivo. We designed a double-blind, placebo-controlled, crossover study to compare the inhibitory effects of bepotastine, cetirizine, fexofenadine, and olopatadine on histamine-induced flare-and-wheal response. Systemic sedative effects and impaired psychomotor activities by these drugs were also evaluated. Bepotastine (10 mg twice a day), cetirizine (10 mg once a day), fexofenadine (60 mg twice a day), and olopatadine (5 mg twice a day) or placebo was given in a double-blind manner to seven healthy volunteers before histamine challenge by iontophoresis. At 0, 1, 2, 4, 8, 12, and 24 h following the oral administration of these drugs, histamine iontophoresis-induced wheal-and-flare response was measured. Sedative effects by the drugs were also evaluated by a visual analogue scale for subjective sedation, and by word processor test for psychomotor activity. Each volunteer was tested with all of the drugs (including placebo), administered in a random order with a washout period of at least 1 week. Histamine iontophoresis induced marked wheal-and-flare response in all participants. Bepotastine, cetirizine, fexofenadine, and olopatadine yielded significant reduction of histamine-induced wheal-and-flare response compared to placebo (P0.01). Among the drugs, olopatadine and cetirizine suppressed most markedly and persistently histamine-induced wheal-and-flare response, while bepotastine and fexofenadine produced a significant, but less persistent suppression. Olopatadine, fexofenadine, and cetirizine showed a significant systemic sedative effect in this order with bepotastine showing the least sedative effect. Moreover, olopatadine affected psychomotor performance most markedly, which was followed by fexofenadine and cetirizine. These results indicate that bepotastine, cetirizine, fexofenadine, and olopatadine inhibit histamine-induced wheal-and-flare response of humans in vivo and induce a variable systemic sedative effect and impaired psychomotor activity. Although olopatadine and cetirizine showed the strongest and most persistent suppression of histamine-induced wheal-and-flare response, olopatadine showed a considerable sedative effect with impaired psychomotor performance."}]}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1380848478892769926","@type":"Researcher","foaf:name":[{"@value":"H. Takahashi"}]},{"@id":"https://cir.nii.ac.jp/crid/1381418520820982018","@type":"Researcher","foaf:name":[{"@value":"A. Ishida-Yamamoto"}]},{"@id":"https://cir.nii.ac.jp/crid/1381418520820982016","@type":"Researcher","foaf:name":[{"@value":"H. Iizuka"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"03076938"},{"@type":"EISSN","@value":"13652230"}],"prism:publicationName":[{"@value":"Clinical and Experimental Dermatology"}],"dc:publisher":[{"@value":"Oxford University Press (OUP)"}],"prism:publicationDate":"2004-09","prism:volume":"29","prism:number":"5","prism:startingPage":"526","prism:endingPage":"532"},"reviewed":"false","dc:rights":["http://doi.wiley.com/10.1002/tdm_license_1.1"],"url":[{"@id":"https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1365-2230.2004.01618.x"},{"@id":"http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2230.2004.01618.x/fullpdf"}],"createdAt":"2004-09-03","modifiedAt":"2023-02-14","foaf:topic":[{"@id":"https://cir.nii.ac.jp/all?q=Adult","dc:title":"Adult"},{"@id":"https://cir.nii.ac.jp/all?q=Male","dc:title":"Male"},{"@id":"https://cir.nii.ac.jp/all?q=Cross-Over%20Studies","dc:title":"Cross-Over Studies"},{"@id":"https://cir.nii.ac.jp/all?q=Pyridines","dc:title":"Pyridines"},{"@id":"https://cir.nii.ac.jp/all?q=Iontophoresis","dc:title":"Iontophoresis"},{"@id":"https://cir.nii.ac.jp/all?q=Cetirizine","dc:title":"Cetirizine"},{"@id":"https://cir.nii.ac.jp/all?q=Dermatitis,%20Atopic","dc:title":"Dermatitis, Atopic"},{"@id":"https://cir.nii.ac.jp/all?q=Double-Blind%20Method","dc:title":"Double-Blind Method"},{"@id":"https://cir.nii.ac.jp/all?q=Piperidines","dc:title":"Piperidines"},{"@id":"https://cir.nii.ac.jp/all?q=Histamine%20H1%20Antagonists","dc:title":"Histamine H1 Antagonists"},{"@id":"https://cir.nii.ac.jp/all?q=Humans","dc:title":"Humans"},{"@id":"https://cir.nii.ac.jp/all?q=Female","dc:title":"Female"},{"@id":"https://cir.nii.ac.jp/all?q=Sleep%20Stages","dc:title":"Sleep Stages"},{"@id":"https://cir.nii.ac.jp/all?q=Terfenadine","dc:title":"Terfenadine"},{"@id":"https://cir.nii.ac.jp/all?q=Olopatadine%20Hydrochloride","dc:title":"Olopatadine Hydrochloride"},{"@id":"https://cir.nii.ac.jp/all?q=Dibenzoxepins","dc:title":"Dibenzoxepins"},{"@id":"https://cir.nii.ac.jp/all?q=Psychomotor%20Performance","dc:title":"Psychomotor Performance"},{"@id":"https://cir.nii.ac.jp/all?q=Histamine","dc:title":"Histamine"}],"relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360846640237539840","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Effects of single therapeutic doses of promethazine, fexofenadine and olopatadine on psychomotor function and histamine-induced wheal- and flare-responses: a randomized double-blind, placebo-controlled study in healthy volunteers"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001204297813888","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Clinical Efficacy of Olopatadine Hydrochloride for Psoriasis Vulgaris with Itching"},{"@language":"ja","@value":"そう痒を伴う尋常性乾癬に対する塩酸オロパタジンの臨床効果の検討"},{"@value":"治療 掻痒を伴う尋常性乾癬に対する塩酸オロパタジンの臨床効果の検討"},{"@language":"ja-Kana","@value":"チリョウ ソウヨウ オ トモナウ ジンジョウセイ カンセン ニ タイスル エンサン オロパタジン ノ リンショウ コウカ ノ ケントウ"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001204298907520","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Examination of Olopatadine Hydrochloride for Anti-itching and Topical-steroid Sparing Effects in Patients with Chronic Eczema or Dermatitis"},{"@language":"ja","@value":"慢性の湿疹・皮膚炎患者に対するオロパタジン塩酸塩の止痒効果およびステロイド外用剤ランクダウン・減量効果の検討"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001204299348608","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"ja","@value":"アトピー性皮膚炎のそう痒，睡眠障害に対する塩酸オロパタジンの有用性及び安全性の検討"},{"@language":"en","@value":"Examination of Utility and Safety of Olopatadine Hydrochloride for Itching and Sleep Disturbance in Atopic Dermatitis"},{"@value":"治療 アトピー性皮膚炎のそう痒,睡眠障害に対する塩酸オロパタジンの有用性及び安全性の検討"},{"@language":"ja-Kana","@value":"チリョウ アトピーセイ ヒフエン ノ ソウ ヨウ スイミン ショウガイ ニ タイスル エンサン オロパタジン ノ ユウヨウセイ オヨビ アンゼンセイ ノ ケントウ"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001204299772544","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Usefulness and Safety of Bepotastine Besilate for Pruritic Skin Disorders"},{"@language":"ja","@value":"そう痒性皮膚疾患に対するベシル酸ベポタスチンの有効性と安全性の検討‐ＶＡＳによる止痒効果および眠気程度の評価‐"},{"@value":"治療 〔ソウ〕痒性皮膚疾患に対するベシル酸ベポタスチンの有効性と安全性の検討--VASによる止痒効果および眠気程度の評価"},{"@language":"ja-Kana","@value":"チリョウ ソウ ヨウセイ ヒフ シッカン ニ タイスル ベシルサン ベポタスチン ノ ユウコウセイ ト アンゼンセイ ノ ケントウ VAS ニ ヨル シヨウコウカ オヨビ ネムケ テイド ノ ヒョウカ"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001204300345472","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Therapeutic Effects of Olopatadine Hydrochloride on Blood Substance P Levels and Circulating Th17 Cell Numbers in Patients with Atopic Dermatitis"},{"@language":"ja","@value":"塩酸オロパタジン内服によるアトピー性皮膚炎患者の血中サブスタンスＰとＴｈ１７細胞割合への影響"},{"@language":"ja-Kana","@value":"エンサン オロパタジン ナイフク ニ ヨル アトピーセイ ヒフエン カンジャ ノ ケッチュウ サブスタンス P ト Th17 サイボウ ワリアイ エ ノ エイキョウ"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001204632602240","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Evaluation of Efficacy and Sedative Profiles of H1 Antihistamines by Large-Scale Surveillance Using the Visual Analogue Scale (VAS)"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282680154721152","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Intact Cell Binding for In Vitro Prediction of Sedative and Non-sedative Histamine H1-Receptor Antagonists Based on Receptor Internalization"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1111/j.1365-2230.2004.01618.x"},{"@type":"OPENAIRE","@value":"doi_dedup___::6e1351ee897d786bc788a55bfe907ad4"},{"@type":"CROSSREF","@value":"10.2336/nishinihonhifu.72.159_references_DOI_6GZ0yKhySCIQ3TGfJWu5krFVA7B"},{"@type":"CROSSREF","@value":"10.1254/jphs.fp0071865_references_DOI_6GZ0yKhySCIQ3TGfJWu5krFVA7B"},{"@type":"CROSSREF","@value":"10.2336/nishinihonhifu.71.526_references_DOI_6GZ0yKhySCIQ3TGfJWu5krFVA7B"},{"@type":"CROSSREF","@value":"10.1007/s00403-011-1192-2_references_DOI_6GZ0yKhySCIQ3TGfJWu5krFVA7B"},{"@type":"CROSSREF","@value":"10.2336/nishinihonhifu.71.438_references_DOI_6GZ0yKhySCIQ3TGfJWu5krFVA7B"},{"@type":"CROSSREF","@value":"10.2336/nishinihonhifu.68.284_references_DOI_6GZ0yKhySCIQ3TGfJWu5krFVA7B"},{"@type":"CROSSREF","@value":"10.2332/allergolint.o-07-525_references_DOI_6GZ0yKhySCIQ3TGfJWu5krFVA7B"},{"@type":"CROSSREF","@value":"10.2336/nishinihonhifu.67.503_references_DOI_6GZ0yKhySCIQ3TGfJWu5krFVA7B"}]}